This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

Tito Serafini Biography and Net Worth

Insider of Atreca

Dr. Serafini is one of the three principal founders of Atreca and was CEO from the Company’s inception in 2010 until 2018. In his role as Chief Strategy Officer, Dr. Serafini is responsible directly for research, preclinical development, technology, and intellectual property. Before co-founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company. Previously, Dr. Serafini was a founder of Renovis, a public biotechnology company, where he served as an executive officer in multiple technical and business management roles, including leading the research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory.

Dr. Serafini received a BS in biochemistry from Case Western Reserve University and a PhD in biochemistry from Stanford University (advised by Dr. James Rothman), and he performed postdoctoral research at the University of California, San Francisco in the laboratory of Dr. Marc Tessier-Lavigne.

What is Tito Serafini's net worth?: The estimated net worth of Tito Serafini is at least $6,684.60 as of August 2nd, 2023. Dr. Serafini owns 72,817 shares of Atreca stock worth more than $6,685 as of April 25th. This net worth evaluation does not reflect any other investments that Dr. Serafini may own. Additionally, Dr. Serafini receives a salary of $665,500.00 as Insider at Atreca. Learn More about Tito Serafini's net worth.
How old is Tito Serafini?: Dr. Serafini is currently 61 years old. There are 3 older executives and no younger executives at Atreca. Learn More on Tito Serafini's age.
What is Tito Serafini's salary?: As the Insider of Atreca, Inc., Dr. Serafini earns $665,500.00 per year. The highest earning executive at Atreca is Mr. John A. Orwin M.B.A., President, CEO, Director & Principal Financial Officer, who commands a salary of $927,030.00 per year. Learn More on Tito Serafini's salary.
How do I contact Tito Serafini?: The corporate mailing address for Dr. Serafini and other Atreca executives is 500 SAGINAW DRIVE FIRST FLOOR, REDWOOD CITY CA, 94063. Atreca can also be reached via phone at (650) 595-2595 and via email at [email protected]. Learn More on Tito Serafini's contact information.
Has Tito Serafini been buying or selling shares of Atreca?: Tito Serafini has not been actively trading shares of Atreca during the last quarter. Most recently, Tito Serafini sold 5,487 shares of the business's stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $0.95, for a transaction totalling $5,212.65. Following the completion of the sale, the insider now directly owns 72,817 shares of the company's stock, valued at $69,176.15. Learn More on Tito Serafini's trading history.
Who are Atreca's active insiders?: Atreca's insider roster includes Norman Greenberg (Insider), William Robinson (Director), and Tito Serafini (Insider). Learn More on Atreca's active insiders.
Are insiders buying or selling shares of Atreca?: In the last twelve months, insiders at the sold shares 3 times. They sold a total of 284,302 shares worth more than $118,980.45. The most recent insider tranaction occured on October, 19th when Major Shareholder Bros. Advisors Lp Baker sold 274,739 shares worth more than $109,895.60. Insiders at Atreca own 11.3% of the company. Learn More about insider trades at Atreca.
Information on this page was last updated on 10/19/2023.

Tito Serafini Insider Trading History at Atreca

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/2/2023	Sell	5,487	$0.95	$5,212.65	72,817
9/2/2022	Sell	7,646	$1.78	$13,609.88	34,554
6/28/2022	Sell	15,000	$2.02	$30,300.00	228,875
3/4/2022	Sell	30,000	$5.00	$150,000.00
9/27/2021	Sell	30,000	$6.58	$197,400.00
3/11/2021	Sell	10,000	$18.31	$183,100.00
2/11/2021	Sell	10,000	$18.93	$189,300.00
1/11/2021	Sell	10,000	$15.02	$150,200.00
12/11/2020	Sell	10,000	$15.87	$158,700.00
11/16/2020	Sell	8,847	$15.12	$133,766.64
10/12/2020	Sell	10,000	$15.00	$150,000.00	3,655
10/6/2020	Sell	1,218	$15.05	$18,330.90	3,655
9/18/2020	Sell	8,782	$15.11	$132,696.02	3,655
8/14/2020	Sell	10,000	$15.00	$150,000.00	3,655
7/13/2020	Sell	10,000	$20.20	$202,000.00	3,655
6/25/2020	Sell	600	$25.01	$15,006.00	3,655
6/22/2020	Sell	496	$20.05	$9,944.80	3,655
6/19/2020	Sell	4,604	$20.03	$92,218.12	3,655
6/11/2020	Sell	10,000	$17.44	$174,400.00	3,655
5/26/2020	Sell	200	$20.00	$4,000.00	3,655
5/11/2020	Sell	10,000	$18.00	$180,000.00	3,655
4/16/2020	Sell	10,000	$16.28	$162,800.00	3,655

Tito Serafini Buying and Selling Activity at Atreca

Atreca Company Overview

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Today's Range

Now: $0.09

$0.08

$0.09

50 Day Range

MA: $0.15

$0.06

$0.31

2 Week Range

Now: $0.09

$0.05

$1.26

Volume

20,249 shs

Average Volume

6,577,037 shs

Market Capitalization

$3.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad

This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

Tito Serafini Biography and Net Worth

What is Tito Serafini's net worth?

How old is Tito Serafini?

What is Tito Serafini's salary?

How do I contact Tito Serafini?

Has Tito Serafini been buying or selling shares of Atreca?

Who are Atreca's active insiders?

Are insiders buying or selling shares of Atreca?